Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The kinetics of virological and biochemical responses in the treatment of chronic hepatitis C by dual antiviral therapy.

Husic-Selimovic A, Vukobrat-Bijedic Z, Huskic J, Bijedic N.

Med Arch. 2012;66(5):300-3.

PMID:
23097965
2.

[Virological sustained response to former young intravenous drug abusers with chronic hepatitis C treated by pegylated interferon-α plus ribavirin].

Gazdíková K, Gazdík F, Kajaba I, Hučková D, Daniš D, Okruhlica L.

Vnitr Lek. 2012 Feb;58(2):104-9. Slovak.

PMID:
22463089
3.

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.

Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group..

J Hepatol. 2013 Aug;59(2):205-12. doi: 10.1016/j.jhep.2013.03.020.

PMID:
23542346
4.

Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.

Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N.

J Gastroenterol. 2011 Nov;46(11):1335-43. doi: 10.1007/s00535-011-0455-1.

PMID:
21858637
5.
6.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

7.

Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.

Miyagi Y, Nomura H, Yamashita N, Tanimoto H, Ito K, Masaki N, Mizokami M, Shibuya T.

J Infect Chemother. 2013 Feb;19(1):63-9. doi: 10.1007/s10156-012-0452-1.

PMID:
22821355
8.
10.

High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.

Gazdik F, Gazdikova K, Laktis K, Okruhlica L, Fejdiova K, Danis D, Pijak MR, Wsolova L, Kajaba I, Kratky A.

Bratisl Lek Listy. 2009;110(2):77-84.

PMID:
19408838
11.

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008516. doi: 10.1002/14651858.CD008516.pub2. Review.

PMID:
22972122
12.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

13.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004.

PMID:
21723079
14.

Real-time PCR assays for hepatitis C virus RNA (genotype 1) is useful for evaluating virological response to the treatment with peginterferon-alpha2b and ribavirin.

Nakaya M, Enomoto M, Fujii H, Kobayashi S, Iwai S, Morikawa H, Tamori A, Sakaguchi H, Kawada N.

Osaka City Med J. 2013 Dec;59(2):79-89.

PMID:
24575583
15.

[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].

Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.

Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):67-73. Czech.

PMID:
18756436
16.

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.

Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L.

Liver Int. 2010 Mar;30(3):447-54. doi: 10.1111/j.1478-3231.2009.02171.x.

PMID:
19919569
17.

Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.

Toyoda H, Kumada T, Tada T, Arakawa T, Hayashi K, Honda T, Katano Y, Goto H.

J Gastroenterol Hepatol. 2010 Jun;25(6):1072-8. doi: 10.1111/j.1440-1746.2010.06240.x.

PMID:
20594221
18.

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.

Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.

J Viral Hepat. 2008 Aug;15(8):591-9. doi: 10.1111/j.1365-2893.2008.00988.x.

PMID:
18482284
19.

Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.

Toyoda H, Kumada T, Tada T, Murakami Y.

J Clin Gastroenterol. 2014 Jan;48(1):73-9. doi: 10.1097/MCG.0b013e31829c409d.

PMID:
23842217
20.
Items per page

Supplemental Content

Support Center